Home » Stocks » Lantheus Holdings

Lantheus Holdings, Inc. (LNTH)

Stock Price: $13.36 USD -0.18 (-1.29%)
Updated Aug 14, 2020 1:03 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 892.29M
Revenue (ttm) 331.84M
Net Income (ttm) 11.63M
Shares Out 66.81M
EPS (ttm) 0.28
PE Ratio 47.70
Forward PE 24.45
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $13.36
Previous Close $13.53
Change ($) -0.18
Change (%) -1.29%
Day's Open 13.49
Day's Range 13.34 - 13.54
Day's Volume 81,776
52-Week Range 8.67 - 27.12

More Stats

Market Cap 892.29M
Enterprise Value 1.03B
Earnings Date (est) Nov 3, 2020
Ex-Dividend Date n/a
Shares Outstanding 66.81M
Float 65.55M
EPS (basic) 0.3
EPS (diluted) 0.28
FCF / Share 1.00
Dividend n/a
Dividend Yield n/a
Earnings Yield 2.10%
FCF Yield 4.83%
Payout Ratio n/a
Shares Short 3.18M
Short Ratio 3.43
Short % of Float 3.66%
Beta 1.16
PE Ratio 47.70
Forward PE 24.45
P/FCF Ratio 20.71
PS Ratio 2.69
PB Ratio 1.77
Revenue 331.84M
Operating Income 22.54M
Net Income 11.63M
Free Cash Flow 43.09M
Net Cash -136.84M
Net Cash / Share -2.05
Gross Margin 52.68%
Operating Margin 6.79%
Profit Margin 3.50%
FCF Margin 12.98%
ROA 3.81%
ROE 3.83%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 2
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$21.67*
(62.26% upside)
Low
16.0
Current: $13.36
High
29.0
Target: 21.67
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue347343331302293302284288
Revenue Growth1.15%3.62%9.78%2.86%-2.7%6.32%-1.54%-
Gross Profit17517516213813612677.3675.20
Operating Income51.6664.4951.8556.5942.5339.42-18.89-0.75
Net Income31.6740.5212326.76-14.75-3.56-61.56-42.00
Shares Outstanding38.9938.2337.2832.0424.4418.0818.03-
Earnings Per Share0.791.033.170.82-0.60-0.20-3.42-0.84
EPS Growth-23.3%-67.51%286.59%-----
Operating Cash Flow80.3861.1954.7849.6421.7611.59-15.57-0.37
Capital Expenditures-22.06-19.13-16.313.21-13.15-7.91-3.48-7.92
Free Cash Flow58.3242.0638.4752.858.613.68-19.06-8.29
Cash & Equivalents92.9211376.2951.1828.6019.7418.580.00
Total Debt194266268278354401407-
Net Cash / Debt-101-153-192-227-325-381-3880.00
Assets406440384256242243261-
Liabilities291369361362428482497-
Book Value11571.0023.29-107-185-239-236-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Lantheus Holdings, Inc.
Country United States
Employees 508
CEO Mary Anne Heino

Stock Information

Ticker Symbol LNTH
Stock Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NASDAQ: LNTH
IPO Date June 25, 2015

Description

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures. The company also offers Xenon, a radiopharmaceutical gas used to assess pulmonary function, and to image cerebral blood flow; Neurolite, an injectable to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable technetium-labeled imaging agent used in myocardial perfusion imaging (MPI) procedures; FDG, a fluorine-18-radiolabeled imaging agent to identify and characterize tumors in patients undergoing oncologic diagnostic procedures; and Cobalt (Co 57), a non-pharmaceutical radiochemical. In addition, it provides injectable radiopharmaceutical imaging agents, such as Thallium TI 201, which is used in MPI studies to detect cardiovascular disease; Gallium Ga 67 that is used to detect various infections and cancerous tumors; and Quadramet, a therapeutic product, which is used to treat severe bone pain associated with metastatic bone lesions. Further, the company is developing Flurpiridaz F 18, which is in Phase III clinical trials to assess blood flow to the heart; and LMI 1195 that is in Phase III clinical trials for the diagnosis and treatment follow-up of neuroendocrine tumors. It sells its products to radiopharmacies, integrated delivery networks, hospitals, clinics, and group practices. The company has a strategic collaboration and license agreement with NanoMab Technology Limited to provide an imaging biomarker research tool to pharmaceutical companies and academic centers conducting research and development on PD-L1 immuno-oncology treatments. The company was founded in 1956 and is headquartered in North Billerica, Mass